XML 246 R14.htm IDEA: XBRL DOCUMENT
v3.22.4

Segment Information | 12 Months Ended
--- | ---
Dec. 31, 2022
Segment Reporting, Measurement Disclosures [Abstract] |
Segment Information | SEGMENT INFORMATION In the fourth quarter of 2022, the Company realigned its reportable segments to reflect changes in the Company’s internal organization resulting from the rate of growth within certain of the Company’s businesses in the former Life Sciences segment. There were no changes to the Company’s Diagnostics or Environmental & Applied Solutions segments. The Company now operates and reports its results in four separate business segments consisting of the Biotechnology, Life Sciences, Diagnostics and Environmental & Applied Solutions segments. When determining the reportable segments, the Company aggregated operating segments based on their similar economic and operating characteristics. Operating profit represents total revenues less operating expenses, excluding nonoperating income and expense, loss on early extinguishment of borrowings, interest and income taxes. Operating profit amounts in the Other segment consist of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance. The identifiable assets by segment are those used in each segment’s operations. Intersegment amounts are not significant and are eliminated to arrive at consolidated totals. Prior period segment amounts have been restated to conform to the revised segment presentation. Detailed segment data for the years ended December 31 is as follows ($ in millions):
| 2022 |  | 2021 |  | 2020
Sales: |  |  |  |  |
Biotechnology | $ | 8,758 |  |  | $ | 8,570 |  |  | $ | 5,276 |
Life Sciences | 7,036 |  |  | 6,388 |  |  | 5,300 |
Diagnostics | 10,849 |  |  | 9,844 |  |  | 7,403 |
Environmental & Applied Solutions | 4,828 |  |  | 4,651 |  |  | 4,305 |
Total | $ | 31,471 |  |  | $ | 29,453 |  |  | $ | 22,284 |
Operating profit: |  |  |  |  |
Biotechnology | $ | 3,008 |  |  | $ | 3,074 |  |  | $ | 1,082 |
Life Sciences | 1,414 |  |  | 1,293 |  |  | 972 |
Diagnostics | 3,436 |  |  | 2,313 |  |  | 1,538 |
Environmental & Applied Solutions | 1,135 |  |  | 1,054 |  |  | 979 |
Other | (305) |  |  | (269) |  |  | (340) |
Total | $ | 8,688 |  |  | $ | 7,465 |  |  | $ | 4,231 |
Depreciation and amortization of intangible assets: |  |  |  |  |
Biotechnology | $ | 1,002 |  |  | $ | 1,059 |  |  | $ | 761 |
Life Sciences | 531 |  |  | 382 |  |  | 292 |
Diagnostics | 590 |  |  | 614 |  |  | 602 |
Environmental & Applied Solutions | 90 |  |  | 106 |  |  | 110 |
Other | 9 |  |  | 7 |  |  | 10 |
Total | $ | 2,222 |  |  | $ | 2,168 |  |  | $ | 1,775 |
The following table presents additional detailed segment data for the years ended December 31 ($ in millions):
| 2022 |  | 2021 |  | 2020
Identifiable assets: |  |  |  |  |
Biotechnology | $ | 37,536 |  |  | $ | 38,118 |  |  | $ | 39,086 |
Life Sciences | 17,572 |  |  | 19,768 |  |  | 9,833 |
Diagnostics | 14,722 |  |  | 15,054 |  |  | 15,042 |
Environmental & Applied Solutions | 4,797 |  |  | 4,882 |  |  | 5,083 |
Other | 9,723 |  |  | 5,362 |  |  | 7,117 |
Total | $ | 84,350 |  |  | $ | 83,184 |  |  | $ | 76,161 |
Capital expenditures, gross: |  |  |  |  |
Biotechnology | $ | 405 |  |  | $ | 385 |  |  | $ | 169 |
Life Sciences | 325 |  |  | 210 |  |  | 137 |
Diagnostics | 382 |  |  | 644 |  |  | 447 |
Environmental & Applied Solutions | 34 |  |  | 54 |  |  | 36 |
Other | 6 |  |  | 1 |  |  | 2 |
Total | $ | 1,152 |  |  | $ | 1,294 |  |  | $ | 791 |
Operations in Geographical Areas:
| Year Ended December 31
($ in millions) | 2022 |  | 2021 |  | 2020
Sales: |  |  |  |  |
United States | $ | 13,365 |  |  | $ | 11,283 |  |  | $ | 8,616 |
China | 4,002 |  |  | 3,975 |  |  | 2,688 |
Germany | 1,461 |  |  | 1,482 |  |  | 1,238 |
All other (each country individually less than 5% of total sales) | 12,643 |  |  | 12,713 |  |  | 9,742 |
Total | $ | 31,471 |  |  | $ | 29,453 |  |  | $ | 22,284 |
Property, plant and equipment, net: |  |  |  |  |
United States | $ | 2,007 |  |  | $ | 1,799 |  |  | $ | 1,317 |
Sweden | 429 |  |  | 513 |  |  | 553 |
United Kingdom | 254 |  |  | 260 |  |  | 214 |
Germany | 225 |  |  | 223 |  |  | 207 |
All other (each country individually less than 5% of total property, plant and equipment, net) | 1,041 |  |  | 995 |  |  | 971 |
Total | $ | 3,956 |  |  | $ | 3,790 |  |  | $ | 3,262 |
Sales by Major Product Group:
| Year Ended December 31
($ in millions) | 2022 |  | 2021 |  | 2020
Analytical and physical instrumentation | $ | 2,846 |  |  | $ | 2,620 |  |  | $ | 2,443 |
Research and medical products | 26,642 |  |  | 24,802 |  |  | 17,979 |
Product identification | 1,983 |  |  | 2,031 |  |  | 1,862 |
Total | $ | 31,471 |  |  | $ | 29,453 |  |  | $ | 22,284 |

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingMeasurementDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration